Does the timing of rituximab introduction in the treatment of diffuse large B-cell non-Hodgkin lymphoma affect progression-free survival?
INTRODUCTION: Diffuse large B-cell lymphoma (DLBCL) is the most prevalent subtype of non-Hodgkin lymphoma. It behaves aggressively, and standard treatment is based on the R-CHOP regimen. Adding rituximab to the protocol has demonstrated clinical benefit, but the impact of the timing of its introduction remains unclear....